The Effect Of Regulation On Pharmaceutical Revenues: Experience In Nineteen Countries
- 1 January 2008
- journal article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 27 (Suppl1) , w125-w137
Abstract
We describe pharmaceutical regulations in nineteen developed countries from 1992 to 2004 and analyze how different regulations affect pharmaceutical revenues. First, there has been a trend toward increased regulation. Second, most regulations reduce pharmaceutical revenues significantly. Third, since 1994, most countries adopting new regulations already had some regulation in place. We find that incremental regulation of this kind had a smaller impact on costs. However, introducing new regulations in a largely unregulated market, such as the United States, could greatly reduce pharmaceutical revenues. Finally, we show that the cost-reducing effects of price controls increase the longer they remain in place.Keywords
This publication has 12 references indexed in Scilit:
- U.S. Pharmaceutical Policy In A Global MarketplaceHealth Affairs, 2008
- Dynamic competition in pharmaceuticals: cross‐national evidence from new drug diffusionManagerial and Decision Economics, 2007
- Assessing Consumer Gains from a Drug Price Control Policy in the United StatesSouthern Economic Journal, 2006
- European prices of newly launched reimbursable pharmaceuticals – a pilot studyHealth Policy, 2005
- The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990sHealth Economics, 2004
- Pharmaceutical Pricing in a Regulated MarketReview of Economics and Statistics, 2003
- The pharmaceutical industry as a medicines providerThe Lancet, 2002
- Do Pharmaceutical Prices Respond to Potential Patient Out-of-Pocket Expenses?The RAND Journal of Economics, 2002
- The Link Between Gross Profitability And Pharmaceutical R&D SpendingHealth Affairs, 2001
- Does Regulation Drive Out Competition in Pharmaceutical Markets?The Journal of Law and Economics, 2000